ArticleJournal of cancer research and clinical oncology2020
Crosstalk of estrogen receptors and Wnt/β-catenin signaling in endometrial cancer.
Article in Journal of cancer research and clinical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 35 citations in OpenAlex.
- Natural Products in Endometrial Cancer: Molecular Mechanisms, Preclinical Evidence, and Clinical Perspectives.Current issues in molecular biology · 2026Review
- Estrogen receptor (ESR) 1 promotes uterine leiomyoma cell proliferation by enhancing mitochondrial energy metabolism via Wnt/β-catenin pathway activation.BMC women's health · 2026Article
- Diagnostic and prognostic potential of microRNA profiles in endometrioid endometrial cancer.Scientific reports · 2025Article
- Selecting Optimal Housekeeping Genes for RT-qPCR in Endometrial Cancer Studies: A Narrative Review.International journal of molecular sciences · 2025Review
- Differential Localization of β-Catenin Protein in CTNNB1 Mutant Endometrial Cancers Results in Distinct Transcriptional Profiles.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2025Article
- Expression of Wnt/β-Catenin Pathway Markers in Ascites Tumor Cells in Ovarian Cancer.Bulletin of experimental biology and medicine · 2025Article
- Focusing on the role of protein kinase mTOR in endometrial physiology and pathology: insights for therapeutic interventions.Molecular biology reports · 2024Review
- A mixture ofHeliyon · 2024Article
- Dkk1 as a Prognostic Marker for Neoadjuvant Chemotherapy Response in Breast Cancer Patients.Cancers · 2024Article
- Oestrogen receptor-independent actions of oestrogen in cancer.Molecular biology reports · 2023Review
- Identification and subsequent validation of transcriptomic signature associated with metabolic status in endometrial cancer.Scientific reports · 2023Article
- Anaplastic lymphoma kinase overexpression enhances aggressive phenotypic characteristics of endometrial carcinoma.BMC cancer · 2023Article
- Role of non‑coding RNA intertwined with the Wnt/β‑catenin signaling pathway in endometrial cancer (Review).Molecular medicine reports · 2023Review
- Loss of Adgra3 causes obstructive azoospermia with high penetrance in male mice.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2023Article
- The association of Wnt-signalling and EMT markers with clinical characteristics in women with endometrial cancer.Frontiers in oncology · 2023Article
- Epigenetic Regulation of Estrogen Receptor Genes' Expressions in Adipose Tissue in the Course of Obesity.International journal of molecular sciences · 2022Article
- Investigation of the Antitumor Effects of Tamoxifen and Its Ferrocene-Linked Derivatives on Pancreatic and Breast Cancer Cell Lines.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Functional interaction between S100A1 and MDM2 may modulate p53 signaling in normal and malignant endometrial cells.BMC cancer · 2022Article
- Estradiol mediates the interaction of LINC01541 and miR-429 to promote angiogenesis of G1/G2 endometrioid adenocarcinomaFrontiers in oncology · 2022Article
- Targeting Wnt Signaling in Endometrial Cancer.Cancers · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate the interaction between Wnt/β-catenin and estrogen signaling pathways in endometrial cancer (EC).
methods119 women were involved in this study, including 65 women with histologically confirmed EC and 54 healthy women as a control group. Serum protein levels of Dkk1 were measured using ELISA. Protein expression levels of Dkk1, β-catenin, ER-β isoforms (β1, β2, β5), and ER-α were tested in paraffin-embedded tissues using IHC. Gene expression levels of Dkk1, CTNNB, ESR1, and ESR2 were tested in fresh tumorous and normal endometrium tissues using RT-PCR.
resultsEC patients had significantly higher serum levels of Dkk1 protein compared with healthy women. Dkk1 and β-catenin showed different expression pattern in tumor cells compared to it in normal cells at the protein level but not at the gene level. Protein expression levels of ERβ2 and ERα were significantly lower in tumor cells compared with tumor-adjacent normal cells. Increased protein expression levels of ERα were associated with favorable clinicopathological features and better overall survival rate (OS). Protein expression levels of ERα were correlated with protein expression levels of Dkk1 and cytoplasmic β-catenin. The association between ERα expression levels and OS was no more significant when tested in regard to Dkk1- and cytoplasmic β-catenin expression levels.
conclusionsOur data demonstrated that Wnt/β-catenin and estrogen signaling systems are dysregulated in EC showing; for the first time, a potential crosstalk between certain components of these two pathways, which in turn has affected the specificity of these molecules in disease characteristics. Understanding the signaling networks in EC is crucial in designing clinical trials to evaluate the efficacy of molecular-targeted agents and providing more successful therapies in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.